Therapeutic antibody expression technology

Current Opinion in Biotechnology

Volumn 12, Issue 2, 2001, Pages 188-194

  Chadd, Helen E ^a   Chamow, Steven M ^a  

^a Abgenix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY;

ANTIBODY STRUCTURE; BACTERIUM CULTURE; BIOREACTOR; CARDIOVASCULAR DISEASE; CELL CULTURE; CONTROLLED STUDY; DRUG COST; DRUG MANUFACTURE; FERMENTATION; HUMAN; INFLAMMATION; MAMMAL CELL; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; REVIEW; TRANSGENIC ANIMAL; TRANSGENIC PLANT;

ANTIBODIES, MONOCLONAL; BIOREACTORS; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; FERMENTATION; HUMANS; IMMUNOGLOBULIN FRAGMENTS; ORGANISMS, GENETICALLY MODIFIED; RECOMBINANT PROTEINS;

ANIMALIA; BACTERIA (MICROORGANISMS); MAMMALIA;

EID: 0035313152     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(00)00198-1     Document Type: Review

References (47)

1. Transgenic mice as a source of fully human antibodies for the treatment of cancer
2. Continuous cultures of fused cells secreting antibody of redefined specificity
3. 4
4. Generation of recombinant antibodies
5. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains
6. Reshaping human antibodies for therapy
7. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties
8. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments
9. Antibody engineering via genetic engineering of the mouse: Xenomouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies
10. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs
11. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice
12. Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM
13. Very high expression of an anti-carcinoembryonic antigen single chain Fv antibody fragment in the yeast Pichia pastoris
14. Recent progress in biomolecular engineering
15. The structural requirements for complement activation by IgG: Does it hinge on the hinge?
16. Human FcγRII interact with distinct but overlapping sites on human IgG
17. Biology of human immunoglobulin G Fc receptors
18. Species-specific variation in glycosylation of IgG: Evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics
19. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity
20. High cytoplasmic expression in E. Coli purification and in vitro refolding of a single chain Fv antibody fragment against the hepatitis B surface antigen
21. Cloning and expression of single chain antibody fragments in Escherichia coli and Pichia pastoris
22. Comparative sensitivity of immunoassays for haptens using monomeric and dimeric antibody fragments
23. Expression of functional recombinant antibody molecules in insect cell expression systems
24. Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies
25. Therapeutic antibody fragments with prolonged in vivo half-lives
26. High level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker
27. Fed-batch culture of recombinant NSO myeloma cells with high monoclonal antibody production
28. Transgenic milk as a method for the production of recombinant antibodies
29. Transgenic production of human therapeutics
30. Feasibility of antibody production in plants for human therapeutic use
31. Antibody-production technologies
32. Foreign protein production in plant tissue cultures
33. Corn seed production of therapeutic proteins moves forward. One company's experience
34. A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes
35. Delivery of immunoprophylactics in transgenic plants
36. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans
37. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
38. A prospective economical evaluation of basiliximab (Simulect) therapy following renal transplantation
39. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
40. Inhibition of platelet-mediated, tissue-factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody; Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'
41. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
42. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus
43. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
44. Ten years of Orthoclone OKT3 (muromonab-CD3): A review
45. Results of a Phase II multicenter study of ABX-CBL monoclonal antibody (anti-CD147) in patients with steroid resistant graft versus host disease (GVHD)
46. Fully human anti-interleukin-8 monoclonal antibodies: Potential therapeutics for the treatment of inflammatory disease states